Company Active LTD

Company profile

Boobybiome Ltd

403 Forbidden

Boobybiome Ltd is a UK company with status active founded in 2019.

CRN
12094202
Founded
2019
Age
6

Overview

Legal name
BOOBYBIOME LTD
Region
Unknown
Registered address
UNIT 3
21 PORTLAND RISE
LONDON
UNITED KINGDOM
UNITED KINGDOM
N4 2PT
Insolvency history
No

Latest accounts

Financial period: 1 Aug 2023 to 31 Jul 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
6

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Apr
2027

Accounts due

Accounts Due

Next accounts due date

14 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jul
2025

Accounts filed

Accounts

Last accounts made up date

30 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

05 Oct
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURDSkpZU0dhZGlxemtjeA | Paper/PDF filed

Published 06 Oct 2024 05:58

09 Jul
2019

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2022
Funded years
2022, 2023, 2024
Age at first award
2 years

Projects

2024 Collaborative R&D Lead participant

Developing clinically efficacious breast milk-derived microbiome supplements for infants.

1 Jun 2024 to 31 Aug 2026

Awarded
£1,038,503
Total cost £1,483,576

**BoobyBiome is developing a breakthrough breast milk-derived synbiotic for infants with compromised microbiomes.** The microbiome describes the microorganisms which reside on and in us. A healthy microbiome is crucial in regulating digestive, immune and metabolic functions. **Human breast milk (BM) contributes 40% of the beneficial bacteria in an infant'...

2024 Collaborative R&D Lead participant

Elucidating the Mechanism of Action of Breast Milk-Derived Synbiotic Consortia in Establishing a Healthy Infant Gut

1 Apr 2024 to 30 Nov 2024

Awarded
£99,936
Total cost £99,936

A healthy microbiome, which describes the microorganisms which reside on and in us, is crucial in regulating digestive, immune and metabolic functions. Breast milk (BM) contributes 40% of the beneficial bacteria in an infant's gut; without it, babies are vulnerable to microbiome-related diseases (necrotising enterocolitis (NEC), sepsis, diabetes, IBS, inc...

2023 Collaborative R&D Lead participant

Development of a novel device to improve the breast milk microbiome

1 May 2023 to 31 Jul 2024

Awarded
£129,114
Total cost £184,448

BoobyBiome is passionate about **empowering parents** and improving the **health of their babies** by designing products which support the infant microbiome. A healthy gut microbiome is crucial in regulating digestive, immune and metabolic functions. The breastmilk microbiome contributes **40%** of the first beneficial gut bacteria to infants. However cur...

2023 Grant for R&D Lead participant

A device for supporting the breast milk microbiome.

1 Apr 2023 to 31 Mar 2024

Awarded
£50,000
Total cost £50,000

The **microbiome** describes the collection of microorganisms, including bacteria, which reside on and in us. A healthy microbiome is crucial in regulating digestive, immune and metabolic functions. Babies **without** access to breastmilk, which **contributes 40%** of the first beneficial bacteria in infants' guts, are **vulnerable** to microbiome-related...

2022 Collaborative R&D Lead participant

The development of a live biotherapeutic product for clinical use, preventing NEC in preterm babies.

1 May 2022 to 30 Apr 2023

Awarded
£197,424
Total cost £282,034

**BoobyBiome is developing breakthrough breast milk-derived live biotherapeutic products (LBPs) for infants with compromised microbiomes**. The microbiome describes the collection of microorganisms, including bacteria, which reside on and in us. A healthy microbiome is crucial in regulating digestive, immune and metabolic functions. Human breast milk (HBM...

Product types

Collaborative R&D Grant for R&D